
Amryt Pharma Holdings Ltd
LSE:AMYT

Net Margin
Amryt Pharma Holdings Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
UK |
![]() |
Amryt Pharma Holdings Ltd
LSE:AMYT
|
453.2m GBP |
-42%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
770.2B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
404.9B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
206.2B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
179.7B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
167.5B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
213.1B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
140.9B USD |
13%
|
Amryt Pharma Holdings Ltd
Glance View
Amryt Pharma Plc is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The firm is focused on developing and commercialization of treatments for orphan and rare diseases patients. The Company’s commercial business provides orphan disease products, which includes Juxtapid/ Lojuxta and Myalept / Myalepta. The Company’s lead development candidate is FILSUVEZ.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Amryt Pharma Holdings Ltd's most recent financial statements, the company has Net Margin of -41.6%.